Kaitlyn A. McKitrick

I'll research this attorney before drafting.

The tracked name has an initial mismatch with search results. Let me dig deeper.

Let me check PTAB/IPR activity and additional case context.

Kaitlyn A. McKitrick (public records: Kaitlyn N. McKitrick), Bowles Rice LLP — N.D. W. Va. / Morgantown and Parkersburg, WV

Practice focus. Ms. McKitrick is not a patent specialist. Her practice, per Bowles Rice's own bio, centers on complex extra-contractual and bad-faith insurance litigation, liability claims, asbestos and toxic-tort/mass-tort defense, product liability, and commercial litigation; she co-leads the firm's Insurance Defense Group. Her only tracked patent matter, and the only patent case in which she appears in public docket records, is the EYLEA® (aflibercept) biosimilar litigation — a pharma/biologics matter involving formulation and manufacturing patents asserted under the BPCIA. No mechanical, software, or standards-essential patent work (e.g., Wi-Fi/SEP matters) is reflected in her record or in any searchable practice description. Treat her as an IP-adjacent litigator whose patent experience is confined to local-counsel coverage in a single biologics MDL, not as a technology-focused patent practitioner.

Side preference. One tracked appearance, on the defendant side (1 defendant / 0 plaintiff). The defendant is Amgen Inc., an operating company and biosimilar applicant — not an NPE/PAE. There is no evidence of plaintiff-side patent prosecution or assertion work.

Firm context. Entire post-law-school career at Bowles Rice: joined as an associate in the Parkersburg office in 2015, elected non-equity partner effective January 2022, and equity partner effective January 1, 2024; she now works primarily from the Morgantown office with a continued Parkersburg presence. No prior law-firm history is publicly reported. Earlier in her career she summered as a law clerk in the Civil Rights Division of the West Virginia Attorney General's Office (2013).

Notable matter. In re Aflibercept Patent Litigation, MDL No. 1:24-md-3103 (N.D. W. Va., Chief Judge Kleeh) — member cases Regeneron Pharmaceuticals, Inc. v. Amgen Inc., Nos. 1:24-cv-39 and 1:25-cv-74. She signed Amgen's answer, written-discovery certificates, and stipulations as West Virginia counsel; Amgen's substantive patent work was handled by national counsel (Marshall, Gerstein & Borun; Rothwell Figg) with Williams & Connolly for Regeneron. Verifiable developments in the matter: the district court denied Regeneron's preliminary injunction against Amgen, and the Federal Circuit affirmed in Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., 130 F.4th 1372 (Fed. Cir. 2025); Amgen subsequently launched PAVBLU® (aflibercept-ayyh). Regeneron later dismissed 15 asserted patents with prejudice by stipulation entered January 7, 2026 (a stipulation she signed), and in March 2026 narrowed its case against Amgen to six selected patents, including U.S. Patent No. 12,331,099, on which Amgen has asserted inequitable conduct and antitrust counterclaims. Co-defendants Mylan/Biocon settled in April 2025 (previously reported). None of these outcomes are attributable to her individually; she appears in a local-counsel capacity.

PTAB / IPR. No IPR, PGR, or other PTAB appearance by this attorney was identified in the available sources. Her name surfaces only in district-court filings and related correspondence in the aflibercept MDL, not in AIA trial papers.

Bar / education. J.D., West Virginia University College of Law (2015; Order of the Coif); B.A. summa cum laude, West Virginia University (2012). Admitted in West Virginia (2015) and Pennsylvania (2023), and to the U.S. District Courts for the Northern and Southern Districts of West Virginia. WV State Bar No. 12782.

Sourcing note. All public professional sources — the Bowles Rice attorney bio, Law360, Martindale, Best Lawyers/Super Lawyers, and N.D. W. Va. filings — identify her as Kaitlyn N. (Nicole) McKitrick. The tracked name "Kaitlyn A. McKitrick" appears to derive from a single 2025 stipulation signature line that used the initial "A." while the same document listed "Kaitlyn N. McKitrick" with her bar number; there is no indication of a separate attorney by that name. If precision matters for a filing, verify the middle initial against her bar record.